ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Average Recommendation of “Moderate Buy” by Analysts

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has been given an average rating of “Moderate Buy” by the twenty research firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $31.2105.

Several equities research analysts have recently issued reports on ACAD shares. UBS Group raised their price target on ACADIA Pharmaceuticals from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Oppenheimer restated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Friday, February 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $34.00 target price on shares of ACADIA Pharmaceuticals in a report on Monday, January 5th. Citizens Jmp lifted their price target on ACADIA Pharmaceuticals from $34.00 to $35.00 and gave the stock a “market outperform” rating in a research report on Thursday, February 26th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a report on Monday, December 29th.

ACADIA Pharmaceuticals Trading Up 0.3%

Shares of ACADIA Pharmaceuticals stock opened at $22.32 on Friday. The firm has a fifty day simple moving average of $23.12 and a 200-day simple moving average of $23.87. ACADIA Pharmaceuticals has a 1-year low of $13.40 and a 1-year high of $28.35. The stock has a market capitalization of $3.81 billion, a price-to-earnings ratio of 9.75, a PEG ratio of 22.13 and a beta of 0.83.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its earnings results on Thursday, February 26th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $1.48. The business had revenue of $298.00 million for the quarter, compared to analyst estimates of $292.54 million. ACADIA Pharmaceuticals had a net margin of 36.49% and a return on equity of 12.49%. ACADIA Pharmaceuticals’s revenue was up 9.4% compared to the same quarter last year. During the same period last year, the business posted $0.86 EPS. As a group, research analysts predict that ACADIA Pharmaceuticals will post 0.7 earnings per share for the current year.

Insider Transactions at ACADIA Pharmaceuticals

In related news, EVP Jennifer J. Rhodes sold 6,950 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $23.38, for a total transaction of $162,491.00. Following the completion of the transaction, the executive vice president directly owned 7,609 shares in the company, valued at $177,898.42. This represents a 47.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 26.50% of the company’s stock.

Institutional Trading of ACADIA Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ACAD. Farther Finance Advisors LLC grew its position in ACADIA Pharmaceuticals by 67.5% during the fourth quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 386 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in ACADIA Pharmaceuticals in the 4th quarter valued at approximately $26,000. Transamerica Financial Advisors LLC raised its holdings in ACADIA Pharmaceuticals by 304.5% in the 4th quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 1,005 shares in the last quarter. Geneos Wealth Management Inc. lifted its position in shares of ACADIA Pharmaceuticals by 113.0% in the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 756 shares during the period. Finally, Federated Hermes Inc. lifted its position in shares of ACADIA Pharmaceuticals by 277.5% in the 4th quarter. Federated Hermes Inc. now owns 1,612 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 1,185 shares during the period. 96.71% of the stock is currently owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.